Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens
Our study identifies a significant cardiotoxic burden following chemotherapy initiation, which is most pronounced with the application of anthracyclines as compared to BTKis. This evidence may benefit patients with lymphoproliferative disorders through prospective cardiovascular assessment and monitoring before, during, and after treatment.
Authors
- Andrew Bonsu
Institutions
- New Cross Hospital (GB)
Publication Details
- Journal
- Cureus
- Published
- 2025-10-21
- DOI
- https://doi.org/10.7759/cureus.95077
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00